Cullinan Therapeutics 正式对外披露，其针对候选药物 CLN-049 与美国食品药品监督管理局（FDA）召开的 I 期结束会议已取得积极反馈。基于这一关键进展，公司决定将该项目推进至一项具有潜在注册意义的 II 期临床研究，针对适应症为急性髓系白血病（AML）。这一举措标志着该药物的开发进程迈入关键阶段。
Cullinan Therapeutics 正式对外披露，其针对候选药物 CLN-049 与美国食品药品监督管理局（FDA）召开的 I 期结束会议已取得积极反馈。基于这一关键进展，公司决定将该项目推进至一项具有潜在注册意义的 II 期临床研究，针对适应症为急性髓系白血病（AML）。这一举措标志着该药物的开发进程迈入关键阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.